EUVIMEDEUVIMED entdecken
Crossref

Esophageal high-resolution manometry can be safely and effectively performed with concurrent glucagon-like peptide-1 receptor agonist use

Khushboo Gala, Preeyati Chopra, Ashwariya Ohri, Mayank Goyal, George Marek, Michael Camilleri iD, Karthik Ravi

Diseases of the Esophagus · 2025

DOI: 10.1093/dote/doaf109 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diseases of the Esophagus, 2025. Verfasst von Khushboo Gala und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA. Hauptthemen laut MEDLINE: Manometry, Glucagon-Like Peptide-1 Receptor Agonists, Esophageal Motility Disorders. Die Arbeit nennt 9 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Esophageal high-resolution manometry (HRM) is the gold standard for evaluating esophageal motility disorders but can be limited by patient intolerance. With increasing use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) for obesity and type 2 diabetes, delayed gastric emptying raises concerns for HRM feasibility and safety. This study assessed HRM tolerability in patients on GLP-1RAs. We conducted a retrospective case–control study of adult patients who underwent HRM at our tertiary care center between January 2014 and November 2024. Patients actively taking GLP-1RAs during HRM were identified as cases, while an equal number of consecutive eligible patients not on GLP-1RAs served as controls. Patients with established gastrointestinal dysmotility, prior foregut surgery, esophageal mechanical obstruction, large hiatal hernias, malignancy, or recent opioid use were excluded. From a prospective database of 7194 HRM attempts, 83 cases and 83 matched controls were identified. Among 166 patients, 15 (9.0%) had incomplete HRM due to intolerance, with similar rates between GLP-1RA users and controls (10.84% vs. 7.2%, P = 0.59). Predictors of incomplete HRM included younger age (44.9 ± 17.4 vs. 60.4 ± 13.7 years, P < 0.01), globus (P = 0.02), dyspepsia (P = 0.02), and depression (P = 0.04). No aspiration or adverse events occurred in either group. Duration of HRM before abortion was similar between cases and controls. GLP-1RA use was not associated with increased risk of HRM abortion or adverse events, suggesting these medications do not significantly impact HRM feasibility or safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ManometryGlucagon-Like Peptide-1 Receptor AgonistsEsophageal Motility DisordersHumansFemaleRetrospective StudiesMaleMiddle AgedCase-Control StudiesAgedAdultDiabetes Mellitus, Type 2Esophagus

Stichwörter der Autor:innen

GLP-1RAesophageal motilityhigh-resolution manometryincomplete procedureobesity

Substanzen

Glucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.

ORCID-Profile: Michael Camilleri

Zitieren

APA

Gala, K., Chopra, P., Ohri, A., Goyal, M., Marek, G., Camilleri, M., & Ravi, K. (2025). Esophageal high-resolution manometry can be safely and effectively performed with concurrent glucagon-like peptide-1 receptor agonist use. Diseases of the Esophagus. https://doi.org/10.1093/dote/doaf109

Vancouver

Gala K, Chopra P, Ohri A, Goyal M, Marek G, Camilleri M, et al. Esophageal high-resolution manometry can be safely and effectively performed with concurrent glucagon-like peptide-1 receptor agonist use. Diseases of the Esophagus. 2025. doi:10.1093/dote/doaf109

BibTeX
@article{Gala2025,
  author = {Gala, Khushboo and Chopra, Preeyati and Ohri, Ashwariya and Goyal, Mayank and Marek, George and Camilleri, Michael and Ravi, Karthik},
  title = {Esophageal high-resolution manometry can be safely and effectively performed with concurrent glucagon-like peptide-1 receptor agonist use},
  journal = {Diseases of the Esophagus},
  year = {2025},
  doi = {10.1093/dote/doaf109}
}
Kostenlos starten →